ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2019
Simplifying Complex Insulin Regimens While Preserving Good Glycemic Control in Type 2 Diabetes.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04020445 (Simplification of Complex Insulin Regimens With Preserving Good Glycemic Control in Type 2 Diabetes), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Simplification of Complex Insulin Regimens With Preserving Good Glycemic Control in Type 2 Diabetes
Who cites it
30 citing papers in PubMed, 56 citations in OpenAlex.
- Insulin therapy DE-intensificAtion with iGlarLixi: A phase 4, open-label, parallel-group randomised controlled trial.Diabetes, obesity & metabolism · 2026Trial
- De-intensification of basal-bolus therapy by replacing prandial insulin with once-weekly subcutaneous semaglutide in individuals with well-controlled type 2 diabetes: A single-centre, open-label randomised trial (TRANSITION-T2D).Diabetes, obesity & metabolism · 2025 · on this mapTrial
- One-year safety and efficacy results of insulin treatment simplification with IDegLira in type 2 diabetes.Endocrinology, diabetes & metabolism · 2023 · on this mapTrial
- Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well-controlled type 2 diabetes: A 24-week randomized controlled trial.Journal of diabetes investigation · 2021Trial
- Oral vs. Subcutaneous Semaglutide for Obesity Treatment: A Systematic Review of Efficacy, Safety, and Patient-Oriented Outcomes.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Burden of Hypoglycemia and Hyperglycemia in Insulin-Treated Veterans Affairs Nursing Home Residents.Journal of the American Geriatrics Society · 2026Article
- Use of Fixed Ratio Combinations to Improve Glycemic Control in Individuals with Type 2 Diabetes: Experts' Opinion from the Gulf Region.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- iGlarlixi for the simplification of more complex insulin regimens in type 2 diabetes patients with good glycaemic control.Frontiers in endocrinology · 2026Observational
- Hypoglycemia-Related Hospitalization in Adults with Type 2 Diabetes Receiving Insulin in Japan: Real-World Analysis Using the Medical Data Vision Database.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist.Diabetes, obesity & metabolism · 2025Review
- What is the 'real-world' experience with fixed-ratio combination therapy (insulin + GLP-1 receptor agonist) in routine clinical practice? Take-home messages for clinicians regarding key outcomes.Diabetes, obesity & metabolism · 2025Review
- Endocrinology: What You May Have Missed in 2024.Annals of internal medicine · 2025Review
- The role of medication regimen complexity in diabetes management: a rapid review.Therapeutic advances in endocrinology and metabolism · 2025Review
- Efficacy of Simplifying Complex Insulin Regimen on Glycometabolic Parameters and Target Organ Damage in Type 2 Diabetes: A Retrospective Cohort Study.Journal of diabetes research · 2025Article
- Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMI.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- SPIRIT: Assessing Clinical Parameters Associated with Using IDegLira in Patients with Type 2 Diabetes in a Real-World Setting in Colombia.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial-Study Design and Protocol.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- De-Intensification from Basal-Bolus Insulin Therapy to Liraglutide in Type 2 Diabetes: Predictive Value of Mean Glycaemia during Fasting Test.Life (Basel, Switzerland) · 2024Article
- Therapeutic Inertia in the Management of Type 2 Diabetes: A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.Diabetes care · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionType 2 diabetic patients suffering from severe hyperglycemia are often assigned a regimen involving multiple daily injections (MDI) of insulin. If the glucose toxicity resolves, the regimen can potentially be simplified, but there are no guidelines for this, and many patients are left on the MDI regimen. We aimed to prospectively examine the safety and efficacy of switching from MDI to once-daily IDegLira, a fixed-ratio combination of insulin degludec and liraglutide, in relatively well controlled (HbA1c ≤ 7.5%) subjects with type 2 diabetes on a low total daily insulin dose (TDD).
methods62 adults with type 2 diabetes (baseline age 64.06 ± 10.24 years, HbA
resultsAfter a mean follow-up period of 99.2 days, mean HbA
conclusionIn everyday clinical practice, switching from low-dose MDI to IDegLira in patients with well-controlled type 2 diabetes is safe, may result in weight loss and similar or better glycemic control, and substantially reduces the insulin requirement. Simplifying complex treatment regimens decreases treatment burden and may improve adherence to therapy. CLINICAL TRIAL NUMBER: NCT04020445.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.